On October 13, 2012, Law et al reported that the Delhi High Court has reserved its verdict in an appeal filed by Cipla challenging an injunction granted by the Delhi High Court in a writ petition filed by Sugen Inc. I thank a friend for bringing this news report to my attention.
The appeal was against a decision of the Single Judge restraining Cipla from taking any steps to market its drug.
Readers may recollect that Sugen Inc’s patent over Sunitinib was revoked last month in a post-grant opposition filed by Cipla.
It would be interesting to see how the High Court decides Cipla’s appeal in light of the revocation of the patent. We will keep our readers updated on the case.